• Explore /
  • Poster
  • / Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.

Everolimus as second-line therapy for metastatic renal cell carcinoma (mRCC) after one previous VEGF-targeted therapy: Final results of the noninterventional change study.

Abstract Poster

Authors

null

Peter J. Goebell

Department of Urology, Friedrich-Alexander University Erlangen, Erlangen, Germany

Peter J. Goebell , Ulrich Kube , Michael Staehler , Christian Doehn , Thomas Steiner , Manfred Kindler , Edwin Herrmann , Jan Janssen , Steffen Weikert , Michael Thomas Scheffler , Joerg Schmitz , Friedrich Overkamp , Gernot Guderian , Michael Albrecht , Lothar Bergmann

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Renal Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 469)

DOI

10.1200/jco.2014.32.4_suppl.469

Abstract #

469

Poster Bd #

F2

Abstract Disclosures

Similar Posters

First Author: Antoine Thiery- Vuillemin

First Author: Jose Manuel Ruiz Morales

Poster

2014 Genitourinary Cancers Symposium

Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.

Duration of targeted therapy in metastatic renal cell carcinoma patients with ECOG PS>2.

First Author: Ilya Tsimafeyeu

First Author: Jiahuai Tan